Technology area: Biotechnology & Pharmaceuticals
34 pending office actions • 14 clients • 29 examiners • 19 art units • 0 of 34 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Biospark Intellectual Property Law has 578 career applications and 33 pending office actions in Biotechnology & Pharmaceuticals. The profile reflects an established application record and an active pending docket in a technically specialized field.
The resolved allowance rate is 70.61%, and the average is 3.5 office actions per allowance. The allowance rate describes outcomes among resolved applications, while the average describes the examination cycles associated with allowed matters. Practitioners should consider the two measures together when planning prosecution, with particular attention to response resources and the technical complexity of the proposed portfolio.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (6%) |
| §103 only | 4 (12%) |
| §102 only | 1 (3%) |
| §112 only | 4 (12%) |
| Double-patenting only | 2 (6%) |
| Double-patenting + other | 5 (15%) |
| Multi-statute (no §101) | 14 (41%) |
| No statute on record | 2 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LU, CHENG | 3 | 53.8% | +64.6% |
| AUDET, MAURY A | 2 | 50.1% | +23.9% |
| SALVOZA, M FRANCO G | 2 | 68.2% | +30.6% |
| DONOGHUE, BRITTNEY ERIN | 2 | 58.7% | +47.4% |
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
| BRAM, STANLEY | 1 | 0.0% | +0.0% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| LIEB, JEANETTE M | 1 | 79.8% | +17.4% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | NICKOL, GARY B | 15d overdue |
| 17055511 | BACTERIAL VECTORS FOR GENETIC MANIPULATION OF BACTERIA | LIPPOLIS, ALEXANDRA ROSE | 12d |
| 18042890 | IMPROVED DEPENDOPARVOVIRUS PRODUCTION COMPOSITIONS AND METHODS | PENNINGTON, KATIE LEIGH | 29d |
| 18452452 | INTERFERON RECEPTOR AGONISTS AND USES THEREOF | JOHNSON, TIRONE DEREK | 34d |
| 18700024 | NANOPARTICULATE FORMULATION | ARNOLD, ERNST V | 46d |
| 18876551 | 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES | BRAM, STANLEY | — |
| 18854185 | METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID BINDING PROTEIN-BASED COMPLEXES | LIEB, JEANETTE M | — |
| 18670301 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | LU, CHENG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | DONOGHUE, BRITTNEY ERIN | 15d overdue |
| 18700024 | NANOPARTICULATE FORMULATION | ARNOLD, ERNST V | 46d |
| 19537081 | CAPSID POLYPEPTIDES AND METHODS OF USE THEREOF | MONTANARI, DAVID A | — |
| 18917773 | COMPOUNDS CONTAINING DEUTERIUM | NOTTINGHAM, KYLE GREGORY | — |
| 18854185 | METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID BINDING PROTEIN-BASED COMPLEXES | LIEB, JEANETTE M | — |
| 18854155 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | AUDET, MAURY A | — |
| 18779855 | CAPSID VARIANTS AND METHODS OF USING THE SAME | SALVOZA, M FRANCO G | — |
| 18761730 | CAPSID VARIANTS AND METHODS OF USING THE SAME | SALVOZA, M FRANCO G | — |
| Art Unit | Apps |
|---|---|
| 1642 | 5 |
| 1672 | 4 |
| 1675 | 3 |
| 1644 | 3 |
| 1691 | 2 |
| 1654 | 2 |
| 1632 | 1 |
| 1621 | 1 |
| 1625 | 1 |
| 1613 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19537081 | CAPSID POLYPEPTIDES AND METHODS OF USE THEREOF | Dyno Therapeutics, Inc. | MONTANARI, DAVID A | 1632 | §112 | Final Rejection | — | Pending | Feb 11, 2026 |
| 18876551 | 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES | BIOVERSYS AG | BRAM, STANLEY | 1691 | §103 | Non-Final OA | — | Pending | Dec 18, 2024 |
| 18917773 | COMPOUNDS CONTAINING DEUTERIUM | Oncopeptides Innovation AB | NOTTINGHAM, KYLE GREGORY | 1621 | §112DP | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18854185 | METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID BINDING PROTEIN-BASED COMPLEXES | Abionyx Pharma SA | LIEB, JEANETTE M | §102§103§112 | Non-Final OA | — | Pending | Oct 04, 2024 | |
| 18854155 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | Abionyx Pharma SA | AUDET, MAURY A | Other | Non-Final OA | — | Pending | Oct 04, 2024 | |
| 18779855 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Dyno Therapeutics, Inc. | SALVOZA, M FRANCO G | 1672 | DP | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18400055 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | Oncopeptides AB | SEAMAN, D MARGARET M | 1625 | §103 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18761730 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Dyno Therapeutics, Inc. | SALVOZA, M FRANCO G | 1672 | DP | Non-Final OA | — | Pending | Jul 02, 2024 |
| 18670314 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. | LU, CHENG | 1642 | §103DP | Non-Final OA | — | Pending | May 21, 2024 |
| 18670301 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. | LU, CHENG | 1642 | §103§112Other | Non-Final OA | — | Pending | May 21, 2024 |
| 18700024 | NANOPARTICULATE FORMULATION | Newimmune Ii, LLC | ARNOLD, ERNST V | 1613 | §103§112Other | Final Rejection | 46d | Pending | Apr 10, 2024 |
| 18615334 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA | Poolbeg Pharma (Uk) Limited | RAHMANI, NILOOFAR | 1691 | §102§112 | Non-Final OA | — | Pending | Mar 25, 2024 |
| 18688464 | ANTI-GLYCO-LAMP1 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. | DAHLE, CHUN WU | 1641 | §112 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18589384 | MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF | Regeneron Pharmaceuticals, Inc. | METCALF, MATTHEW CURRAN | 1647 | §102§103DP | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18417702 | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | The Sydney Children's Hospitals Network | LEONARD, ARTHUR S | 1631 | §102§103 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18576878 | MELFLUFEN FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | Oncopeptides Innovation AB | JAUHARI, SACHI | 1654 | §102§103§112Other | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18573582 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Dyno Therapeutics, Inc. | CHESTNUT, BARRY A | 1672 | §102 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18571367 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Dyno Therapeutics, Inc. | CORNELIUS, CLAIRE ADRIENNE | 1672 | §101§112 | Final Rejection | — | Pending | Dec 18, 2023 |
| 18554688 | USE OF LIPID BINDING PROTEIN-BASED COMPLEXES IN ORGAN PRESERVATION SOLUTIONS | Abionyx Pharma SA | KOSAR, AARON J | 1655 | — | Non-Final OA | — | Pending | Oct 10, 2023 |
| 18548772 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. | LU, CHENG | 1642 | §112DP | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18452452 | INTERFERON RECEPTOR AGONISTS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. | JOHNSON, TIRONE DEREK | 1675 | §103§112Other | Non-Final OA | 34d | Pending | Aug 18, 2023 |
| 18324380 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112 | Non-Final OA | — | Pending | May 26, 2023 |
| 18133288 | COMPOSITIONS AND METHODS FOR UNIVERSAL TUMOR CELL KILLING | Regeneron Pharmaceuticals, Inc. | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Non-Final OA | — | Pending | Apr 11, 2023 |
| 18247465 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | Abionyx Pharma SA | AUDET, MAURY A | 1654 | §103 | Final Rejection | — | Pending | Mar 31, 2023 |
| 18042890 | IMPROVED DEPENDOPARVOVIRUS PRODUCTION COMPOSITIONS AND METHODS | Dyno Therapeutics, Inc. | PENNINGTON, KATIE LEIGH | 1634 | §103§112 | Final Rejection | 29d | Pending | Feb 24, 2023 |
| 18003279 | IMMUNOTHERAPY | Neogap Therapeutics AB | JUEDES, AMY E | 1644 | §103DP | Final Rejection | — | Pending | Dec 23, 2022 |
| 17928803 | NUCLEIC ACID ENCODING AN ANTI-VEGF ENTITY AND A NEGATIVE COMPLEMENT REGULATOR AND USES THEREOF FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Gyroscope Therapeutics Limited | XIAO, YAN | 1642 | §102§103§112 | Non-Final OA | — | Pending | Nov 30, 2022 |
| 17928798 | METHODS OF PRODUCING RECOMBINANT COMPLEMENT PROTEINS, VECTORS AND THERAPEUTIC USES THEREOF | Novartis Pharmaceuticals UK Limited | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §103§112 | Non-Final OA | — | Pending | Nov 30, 2022 |
| 17909045 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. | GEORGE, DENNIS CHERIAN | 1644 | §101§103§112DP | Non-Final OA | — | Pending | Sep 02, 2022 |
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | §103 | Non-Final OA | 15d overdue | Pending | Aug 15, 2022 |
| 17735510 | MULTISPECIFIC FGF21 RECEPTOR AGONISTS AND THEIR USES | Regeneron Pharmaceuticals, Inc. | SAOUD, CHRISTINE J | 1600 | §112 | Non-Final OA | — | Pending | May 03, 2022 |
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | Novartis AG | NICKOL, GARY B | 1643 | §102§103 | Final Rejection | 15d overdue | Pending | Dec 20, 2021 |
| 17417601 | PHAGOCYTISABLE PARTICLE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCER | Neogap Therapeutics AB | JOHANSEN, PETER N. | 1644 | §112 | Non-Final OA | 17d overdue | Pending | Jun 23, 2021 |
| 17055511 | BACTERIAL VECTORS FOR GENETIC MANIPULATION OF BACTERIA | BIOVERSYS AG | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103§112 | Final Rejection | 12d | Pending | Nov 13, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial70.6% of resolved applications prosecuted by Biospark Intellectual Property Law were allowed, across 578 applications in USPTO records.
3.50 office actions per allowed application on average.
34 pending office actions as of October 2026, for 14 clients, before 29 examiners in 19 art units.
